Perrigo Company Appoints FDA Veteran As New Head Of Regulatory Review

ALLEGAN, Mich., Sept. 20, 2013 /PRNewswire/ -- Perrigo Company (NYSE: PRGO; TASE) today announced the appointment of Keith Webber as Head of Regulatory Review, effective October 21, 2013. This new role will have responsibility for advancing the approval of all of Perrigo's Consumer Healthcare (CHC) and Prescription Pharmaceutical (Rx) regulatory applications pending with the U.S. Food and Drug Administration (FDA), providing guidance on scientific and regulatory strategy for new CHC and Rx pipeline products under development, and continuously advancing the quality of new regulatory applications. 

(Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO)

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "I am excited to welcome Keith to the Perrigo family. He brings to us a wealth of strategic, scientific and regulatory experience from his years working with the FDA. Keith will work closely with regulatory leadership to support new product selection and develop strategies and processes to achieve high quality applications and timely approvals, enabling us to bring quality, affordable products to the market."

Prior to accepting the Perrigo position, Keith served as Acting Director of the Office of the FDA's Pharmaceutical Science in the Center for Drug Evaluation and Research (CDER), which regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. Prior to that, he served as Director of Office of Generic Drug (OGD), where he directed FDA regulation of generic pharmaceuticals including, legal, chemistry, bioequivalence, microbiology, clinical and labeling. He also served in several leadership roles within the FDA responsible for regulating pharmaceutical quality, biopharmaceutical drug development and monoclonal antibody-related biopharmaceuticals research and review. Keith earned a Bachelor of Science degree in Chemistry from the University of Denver and a Doctor of Philosophy degree from the University of Michigan.

From its beginnings as a packager of generic home remedies in 1887, Allegan, Michigan-based Perrigo Company has grown to become a leading global provider of quality, affordable healthcare products. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements and active pharmaceutical ingredients (API). The company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The company's primary markets and locations of logistics operations have evolved over the years to include the United States, Israel, Mexico, the United Kingdom, India, China and Australia. Visit Perrigo on the Internet at www.perrigo.com.

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2012, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Perrigo Company